Does Rallies show 13F holders for GLSI?

Yes. Rallies tracks hedge fund and 13F ownership data for GLSI, including fund names, share counts, latest tracked quarter, and position changes when available.

Is GLSI research on Rallies investment advice?

No. Rallies provides research, data, and educational context for GLSI. It does not provide personalized investment advice.

GLSI (Greenwich LifeSciences, Inc.) Stock Analysis - Hedge Fund Holdings

Greenwich LifeSciences, Inc. (GLSI) is a publicly traded Healthcare sector company. As of May 21, 2026, GLSI trades at $26.82 with a market cap of $372.41M and a P/E ratio of -22.14. GLSI moved +3.57% today. Year to date, GLSI is +28.81%; over the trailing twelve months it is +165.24%. Its 52-week range spans $7.78 to $34.10. Analyst consensus is buy with an average price target of $47.50. Rallies surfaces GLSI's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns GLSI stock?

Hedge funds tracked by Rallies that own GLSI include Renaissance Technologies. The latest tracked quarter is Dec 31, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Greenwich LifeSciences, Inc..

GLSI Key Metrics

Key financial metrics for GLSI
Metric	Value
Price	$26.82
Market Cap	$372.41M
P/E Ratio	-22.14
EPS	$-1.21
Dividend Yield	0.00%
52-Week High	$34.10
52-Week Low	$7.78
Volume	816
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-15.79M
Gross Margin	0.00%

Top Hedge Funds Holding GLSI

Renaissance Technologies holds 22.70K shares of GLSI, changed -30.15% as of Dec 31, 2024.

Latest GLSI News

Greenwich LifeSciences delays FY2025 10-K, FLAMINGO-01 arm shows 70-80% recurrence drop — Apr 30, 2026
Greenwich LifeSciences Reports 70-80% Recurrence Reduction Data in 250 Patients — Apr 23, 2026
Greenwich LifeSciences Raises Cash to $10.5M; Phase III Arm Shows 70–80% Recurrence Reduction — Apr 14, 2026
Greenwich LifeSciences Files Patent Claims to Double GP2 Market to 88,000 Patients — Apr 7, 2026
Greenwich LifeSciences Expands FLAMINGO-01 Trial to Up to 200 Sites with City of Hope — Mar 19, 2026

Recent GLSI Insider Trades

Patel Snehal bought 1.80K (~$53.69K) on Jan 13, 2026.
Patel Snehal bought 2.90K (~$79.87K) on Jan 12, 2026.
Patel Snehal bought 4.30K (~$91.85K) on Dec 31, 2025.

GLSI Analyst Consensus

2 analysts cover GLSI: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $47.50.

Common questions about GLSI

Who owns GLSI stock?: Hedge funds tracked by Rallies that own GLSI include Renaissance Technologies. The latest tracked quarter is Dec 31, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Greenwich LifeSciences, Inc..
Does Rallies show 13F holders for GLSI?: Yes. Rallies tracks hedge fund and 13F ownership data for GLSI, including fund names, share counts, latest tracked quarter, and position changes when available.
Is GLSI research on Rallies investment advice?: No. Rallies provides research, data, and educational context for GLSI. It does not provide personalized investment advice.